Teva and mabxience announce strategic global licensing agreement for oncology biosimilar candidate

Tel aviv, israel, & madrid--(business wire)--teva pharmaceuticals international gmbh, a subsidiary of teva pharmaceutical industries ltd. (nyse and tase: teva) and mabxience, a fresenius kabi majority-owned group with partial ownership from insud pharma, today announced they have entered a strategic licensing agreement for a biosimilar candidate currently in development for the treatment of multiple oncology indications. biosimilars show promising potential in providing more cost-effective alte.
TEVA Ratings Summary
TEVA Quant Ranking